Neos Therapeutics (NASDAQ:NEOS) Cut to “Hold” at Zacks Investment Research

Zacks Investment Research lowered shares of Neos Therapeutics (NASDAQ:NEOS) from a buy rating to a hold rating in a report published on Friday morning, Zacks.com reports.

According to Zacks, “Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. “

A number of other research firms have also commented on NEOS. Cantor Fitzgerald reaffirmed an overweight rating and issued a $130.00 price objective (up from $116.00) on shares of Zoetis in a research note on Wednesday, June 12th. ValuEngine lowered Zosano Pharma from a buy rating to a hold rating in a research note on Wednesday, May 1st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. The stock has an average rating of Hold and a consensus target price of $6.88.

Neos Therapeutics stock opened at $1.41 on Friday. The business has a 50 day moving average of $1.37. The company has a debt-to-equity ratio of 41.70, a quick ratio of 1.27 and a current ratio of 1.49. The firm has a market capitalization of $70.11 million, a price-to-earnings ratio of -0.88 and a beta of 1.19. Neos Therapeutics has a one year low of $1.13 and a one year high of $6.30.

Neos Therapeutics (NASDAQ:NEOS) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.15) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.07. The company had revenue of $14.63 million during the quarter, compared to analyst estimates of $14.20 million. As a group, analysts predict that Neos Therapeutics will post -0.61 EPS for the current year.

Institutional investors have recently bought and sold shares of the stock. BNP Paribas Arbitrage SA lifted its stake in shares of Neos Therapeutics by 1,749.5% in the first quarter. BNP Paribas Arbitrage SA now owns 10,098 shares of the company’s stock worth $26,000 after acquiring an additional 9,552 shares during the period. Alambic Investment Management L.P. acquired a new position in Neos Therapeutics in the first quarter valued at approximately $32,000. Two Sigma Investments LP acquired a new position in Neos Therapeutics in the fourth quarter valued at approximately $35,000. American International Group Inc. lifted its stake in Neos Therapeutics by 63.9% in the fourth quarter. American International Group Inc. now owns 30,814 shares of the company’s stock valued at $51,000 after buying an additional 12,016 shares during the period. Finally, Jane Street Group LLC acquired a new position in Neos Therapeutics in the fourth quarter valued at approximately $62,000. 54.87% of the stock is currently owned by institutional investors.

Neos Therapeutics Company Profile

Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.

Read More: Stock Symbols and CUSIP Explained

Get a free copy of the Zacks research report on Neos Therapeutics (NEOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.